Multidisciplinary Association for Psychedelic Studies: Difference between revisions
>Unity lol |
>Tracer Changed external links |
||
| (3 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
'''Multidisciplinary Association for Psychedelic Studies (MAPS)''' is a membership-based 501(c)(3) organization working to raise awareness and understanding of [[Psychedelic|psychedelic substances]]. MAPS was founded in 1986 by Rick Doblin, and is now based in Santa Cruz, California. | |||
'''Multidisciplinary Association for Psychedelic Studies (MAPS)''' is a membership-based 501(c)(3) organization working to raise awareness and understanding of psychedelic substances. MAPS was founded in 1986 by Rick Doblin, and is now based in Santa Cruz, California. | |||
MAPS helps scientists design, fund, and obtain regulatory approval for studies of the safety and effectiveness of a number of controlled substances. MAPS works closely with government regulatory authorities worldwide such as the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) to ensure that all of its sponsored research protocols conform to ethical and procedural guidelines for clinical drug research. | MAPS helps scientists design, fund, and obtain regulatory approval for studies of the safety and effectiveness of a number of controlled substances. MAPS works closely with government regulatory authorities worldwide such as the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) to ensure that all of its sponsored research protocols conform to ethical and procedural guidelines for clinical drug research. | ||
Included in MAPS’ research efforts are MDMA (methylenedioxymethamphetamine) for the treatment of posttraumatic stress disorder (PTSD); LSD and psilocybin for the treatment of anxiety, cluster headaches, and depression associated with end-of-life issues; ibogaine for the treatment of opiate addiction, ayahuasca for the treatment of drug addiction and PTSD; medical | Included in MAPS’ research efforts are [[MDMA]] (methylenedioxymethamphetamine) for the treatment of posttraumatic stress disorder (PTSD); [[LSD]] and [[psilocybin]] for the treatment of [[anxiety]], cluster [[headaches]], and [[depression]] associated with end-of-life issues; [[ibogaine]] for the treatment of [[opiate]] addiction, [[ayahuasca]] for the treatment of drug addiction and PTSD; medical [[cannabis]] for PTSD; and alternative delivery systems for medical marijuana such as vaporizers and water pipes. MAPS officials say the organization's ultimate goal is to establish a network of clinics where these and other treatments can be provided together with other therapies under the guidance of trained, licensed physicians and therapists. | ||
==External links== | ==External links== | ||
*[https://en.wikipedia.org/wiki/Multidisciplinary_Association_for_Psychedelic_Studies (Wikipedia)] | *[https://maps.org Multidisciplinary Association for Psychedelic Studies (Website)] | ||
*[https://en.wikipedia.org/wiki/Multidisciplinary_Association_for_Psychedelic_Studies Multidisciplinary Association for Psychedelic Studies (Wikipedia)] | |||
[[Category:Organization]] | |||
Latest revision as of 13:44, 17 October 2021
Multidisciplinary Association for Psychedelic Studies (MAPS) is a membership-based 501(c)(3) organization working to raise awareness and understanding of psychedelic substances. MAPS was founded in 1986 by Rick Doblin, and is now based in Santa Cruz, California.
MAPS helps scientists design, fund, and obtain regulatory approval for studies of the safety and effectiveness of a number of controlled substances. MAPS works closely with government regulatory authorities worldwide such as the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) to ensure that all of its sponsored research protocols conform to ethical and procedural guidelines for clinical drug research.
Included in MAPS’ research efforts are MDMA (methylenedioxymethamphetamine) for the treatment of posttraumatic stress disorder (PTSD); LSD and psilocybin for the treatment of anxiety, cluster headaches, and depression associated with end-of-life issues; ibogaine for the treatment of opiate addiction, ayahuasca for the treatment of drug addiction and PTSD; medical cannabis for PTSD; and alternative delivery systems for medical marijuana such as vaporizers and water pipes. MAPS officials say the organization's ultimate goal is to establish a network of clinics where these and other treatments can be provided together with other therapies under the guidance of trained, licensed physicians and therapists.